Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
IPO Year: 2000
Exchange: NYSE
Website: criver.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/21/2025 | $190.00 → $170.00 | Buy → Neutral | Goldman |
| 3/4/2025 | $155.00 → $175.00 | Sell → Neutral | Citigroup |
| 3/3/2025 | $188.00 | Sell → Neutral | Redburn Atlantic |
| 1/22/2025 | Outperform → Mkt Perform | William Blair | |
| 1/17/2025 | $250.00 → $185.00 | Buy → Neutral | UBS |
| 11/18/2024 | $164.00 | Hold → Underperform | CLSA |
| 11/7/2024 | $205.00 | Underperform → Hold | CLSA |
| 10/23/2024 | $167.00 | Underperform | CLSA |
| 10/14/2024 | Sell | Redburn Atlantic | |
| 10/7/2024 | $225.00 → $190.00 | Outperform → In-line | Evercore ISI |
Goldman downgraded Charles River from Buy to Neutral and set a new price target of $170.00 from $190.00 previously
Citigroup upgraded Charles River from Sell to Neutral and set a new price target of $175.00 from $155.00 previously
Redburn Atlantic upgraded Charles River from Sell to Neutral and set a new price target of $188.00
William Blair downgraded Charles River from Outperform to Mkt Perform
UBS downgraded Charles River from Buy to Neutral and set a new price target of $185.00 from $250.00 previously
CLSA downgraded Charles River from Hold to Underperform and set a new price target of $164.00
CLSA upgraded Charles River from Underperform to Hold and set a new price target of $205.00
CLSA initiated coverage of Charles River with a rating of Underperform and set a new price target of $167.00
Redburn Atlantic initiated coverage of Charles River with a rating of Sell
Evercore ISI downgraded Charles River from Outperform to In-line and set a new price target of $190.00 from $225.00 previously
First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering's in-house drug development unit Charles River Laboratories International, Inc. (NYSE:CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet need. The discovery is the first using Logica®, an artificial intelligence (AI)-powered drug development solution that translates biological insights into optimized preclinical assets. "Identification of this first lead candidate provides proof-of-concept for Logica as a
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, at 9:30 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and services to help p
Charles River to provide master cell banking and NGS testing services for cord blood derived allogeneic CAR-T cells Charles River Laboratories International, Inc. (NYSE:CRL) today announced an agreement with Singapore General Hospital (SGH) to provide Current Good Manufacturing Practice (CGMP) -compliant master cell banking (MCB) and next-generation sequencing (NGS)-based services for use in cell line characterization. SGH will use cord blood to derive and manufacture allogeneic chimeric antigen receptor (CAR) T-cells which will be used to treat patients with cancer. "We are thrilled to leverage our cell line characterization services and comprehensive NGS testing approach to support SG
– Fourth-Quarter Revenue of $1.00 Billion and Full-Year Revenue of $4.05 Billion – – Fourth-Quarter GAAP Loss per Share of $(4.22) and Non-GAAP Earnings per Share of $2.66 – – Full-Year GAAP Earnings per Share of $0.20 and Non-GAAP Earnings per Share of $10.32 – – Provides 2025 Guidance – – Company Plans Stock Repurchases of Approximately $350 Million in 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2024 and provided guidance for 2025. For the quarter, revenue was $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023. The impact of foreign currency translation reduced report
Charles River Laboratories International, Inc. (NYSE:CRL) and Deciphex, a leader in AI-powered digital pathology, today announced the next phase of a strategic collaboration to focus on advancing cutting-edge image management solutions, while continuing to develop novel artificial intelligence (AI) tools for toxicologic pathology. Together, Deciphex and Charles River will deliver a fully integrated image management, distribution, and archiving workflow designed to maximize efficiency, precision, and scalability in pathology workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211084115/en/ "Patholytix has transformed how
Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2024 financial results and provide 2025 guidance on Wednesday, February 19th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 19th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leadi
Launch of Apollo™ for CRADL® provides a secure cloud-based platform to enhance access to services and visibility across teams and processes Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of Apollo™ for CRADL®, a secure cloud-based platform that enhances leading vivarium rental services through a digital platform that connects clients effortlessly with the training, tools and services needed to start research quickly. As a digital companion to CRADL's existing rental space offering, Apollo's centralized dashboard seamlessly connects clients to online training, Charles River's Research Models Online Ordering System, and other study support services. "
Charles River Laboratories International, Inc. (NYSE:CRL) and Akron Bio ("Akron"), a leading supplier of critical materials and services for advanced therapies, today announced the integration of Akron's Closed System Solutions (CSS)™ line of liquid cytokines produced under current good manufacturing practices (CGMP) onto Charles River's Cell Therapy Flex Platform for Process Development. The integration of Akron's line of liquid cytokines further enables closed system processing, which streamlines operations, minimizes risk, and improves process robustness. Charles River's Cell Therapy Flex Platform was designed as an off-the-shelf solution for Cell Therapy Process Development, offering
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and serv
Deciphex, a leader in AI-powered digital pathology, has closed its Series C financing, raising $32.3 million to address the acute global pathology crisis. Led by Molten Ventures with significant participation from ACT Venture Capital, Seroba, Charles River Laboratories (NYSE:CRL), IRRUS Investments, HBAN Medtech Syndicate and Nextsteps Capital, the funding will advance Deciphex's mission to democratize access to high-quality pathology through a technology-enabled global network of pathologists. With over 70% of healthcare decisions requiring pathology investigation and a widening gap between rising patient needs and declining pathologist numbers, healthcare systems face mounting backlogs
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commercial organizations that will provide a wealth of healthcare business leadership knowledge and sales and marketing expertise to Charles River's Board. As a member of the Board, Ms. Kemps-Polanco will serve on the Compensation and Strategic Planning and Capital Allocation Committees. "Reshema Kemp-Polanco's deep industry experience at two of the top-10, global pharmaceutical companies and demonstrated
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology researchCharles River to make an equity investment in Aitia as part of the agreementWILMINGTON, Mass. and SOMERVILLE, Mass., Nov. 13, 2023 /PRNewswire/ -- Charles River Laboratories International, Inc. (NYSE:CRL) and Aitia, a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™, Charles River's Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the agreement Charles River Laboratories International, Inc. (NYSE:CRL) and Aitia, a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™, Charles River's Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology. This press release features multimedia. View the full release here: https://www.bu
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the re-appointment of Craig B. Thompson, M.D., former President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center, to its Board of Directors. Dr. Thompson previously served as a member of Charles River's Board of Directors from 2013 through 2018. Dr. Thompson's extensive scientific expertise in the fields of immuno-oncology and translational and precision medicine, together with his healthcare business leadership experience, will provide a unique contribution of knowledge and guidance to Charles River's Board. As a member of the Board, he will serve on the Science and Technology and Strategic Plannin
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
144 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
10-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
10-Q - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
10-Q - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
– Fourth-Quarter Revenue of $1.00 Billion and Full-Year Revenue of $4.05 Billion – – Fourth-Quarter GAAP Loss per Share of $(4.22) and Non-GAAP Earnings per Share of $2.66 – – Full-Year GAAP Earnings per Share of $0.20 and Non-GAAP Earnings per Share of $10.32 – – Provides 2025 Guidance – – Company Plans Stock Repurchases of Approximately $350 Million in 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2024 and provided guidance for 2025. For the quarter, revenue was $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023. The impact of foreign currency translation reduced report
Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2024 financial results and provide 2025 guidance on Wednesday, February 19th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 19th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leadi
– Third-Quarter Revenue of $1.01 Billion – – Third-Quarter GAAP Earnings per Share of $1.33 and Non-GAAP Earnings per Share of $2.59 – – Updates 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion in the third quarter of 2023. The impact of foreign currency translation benefited reported revenue by 0.4%, and an acquisition contributed 0.9% to consolidated third-quarter revenue. A divestiture of a small Safety Assessment site reduced reported revenue by 0.2%. Excluding the effect of these items, revenue declined 2.7% on an organ
Charles River Laboratories International, Inc. (NYSE:CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 6th, at 9:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe acce
– Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.74 and Non-GAAP Earnings per Share of $2.80 – – Board Approves New Stock Repurchase Authorization of $1.0 Billion – – Revises 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the second quarter of 2024. For the quarter, revenue was $1.03 billion, a decrease of 3.2% from $1.06 billion in the second quarter of 2023. The impact of foreign currency translation reduced reported revenue by 0.3%, a divestiture reduced reported revenue by 0.2%, and an acquisition contributed 0.5% to consolidated second-quarter revenue. Excluding the effect of t
Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2024 financial results on Wednesday, August 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe acce
– First-Quarter Revenue of $1.01 Billion – – First-Quarter GAAP Earnings per Share of $1.30 and Non-GAAP Earnings per Share of $2.27 – – Updates 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03 billion in the first quarter of 2023. The impact of foreign currency translation benefited reported revenue by 0.3%, and acquisitions contributed 1.5% to consolidated first-quarter revenue. A small divestiture of a Safety Assessment site reduced reported revenue by 0.2%. Excluding the effect of these items, organic revenue decreased 3.3%.
Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate thei
– Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP Earnings per Share of $10.67 – – Provides 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth-quarter and full-year 2023 and provided guidance for 2024. For the quarter, revenue was $1.01 billion, a decrease of 7.9% from $1.10 billion in the fourth quarter of 2022. The impact of foreign currency translation benefited reported revenue by 1.2%, and acquisitions contributed 0.7% to consolida
Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2023 financial results and provide 2024 guidance on Wednesday, February 14th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 14th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leadi
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)